Whole-Body Dosimetry for Individualized Treatment Planning of ¹³¹I-MIBG Radionuclide Therapy for Neuroblastoma

Abstract

The results indicate that even in a highly heterogeneous and heavily pretreated patient population, a whole-body absorbed dose can be prescribed accurately and is a more accurate predictor of hematologic toxicity than is administered activity. Therefore, a whole-body absorbed dose can be used to deliver accurate and reproducible (131)I-MIBG therapy on a patient-specific basis.